To test or not to test? Targeted therapies in GU Cancers – leveraging new advances in clinical care

Share :
Published: 7 Apr 2024
Views: 2443
Prof Eva Compérat, Dr Friederike Schlürmann and Dr Guilhem Roubaud

Watch this interactive seminar from EAU 2024 in Paris, featuring:

Chair: Prof. Eva Compérat

Welcome & introduction:
Prof. Eva Compérat

Biomarker breakthroughs: how can we utilise biomarkers in urothelial cancer?:
Dr. Friederike Schlürmann

Testing...testing 1,2,3: what is the value of identifying BRCA1 and BRCA2 mutations for mCRPC outcomes?:
Dr. Guilhem Roubaud

Case studies in precision medicine: real-world applications in GU oncology:
All faculty

Summary and close:
Prof. Eva Compérat

The session is part of a series of 3:

This industry seminar is funded and organised by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA and is intended for healthcare professionals only. Document for non-French physicians. Janssen-Cilag International NV.